Literature DB >> 22865326

Sacral chordoma: management of a rare disease in a tertiary hospital.

Gada Housari1, Mariana González, Purificación Calero, Rafael Beni, Eduardo Lobo.   

Abstract

INTRODUCTION: Chordoma is a rare malignant bone tumor. The outcome depends on the adequate surgical treatment with complete excision of the tumor with microscopic clear margins.
MATERIALS AND METHODS: We performed a retrospective review of 13 cases of chordomas operated in our center between 1988 and 2009.
RESULTS: All cases were treated with wide excision. Inadequate margins were found in seven patients. There were complications in ten patients and long-term sequels in 11 patients. Nine had recurrence within the first 2 years, six of which had inadequate margins. Five had metastatic disease, three of them with inadequate margins. During the follow-up, four patients died. In a posterior review, three patients survive and all of them had clear margins.
CONCLUSIONS: In our experience, the best treatment is complete excision of the tumor with clear microscopic margins. When this is not possible, local recurrences increase and survival rate decreases.

Entities:  

Mesh:

Year:  2012        PMID: 22865326     DOI: 10.1007/s12094-012-0919-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  12 in total

1.  The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.

Authors:  Asem Shalaby; Nadège Presneau; Hongtao Ye; Dina Halai; Fitim Berisha; Bernadine Idowu; Andreas Leithner; Bernadette Liegl; Timothy R W Briggs; Krisztian Bacsi; Lars-Gunnar Kindblom; Nicholas Athanasou; Maria Fernanda Amary; Pancras C W Hogendoorn; Roberto Tirabosco; Adrienne M Flanagan
Journal:  J Pathol       Date:  2010-12-10       Impact factor: 7.996

2.  Carbon ion radiotherapy for sacral chordoma.

Authors:  R Imai; T Kamada; S Sugahara; H Tsuji; H Tsujii
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

3.  Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients.

Authors:  P Bergh; L G Kindblom; B Gunterberg; F Remotti; W Ryd; J M Meis-Kindblom
Journal:  Cancer       Date:  2000-05-01       Impact factor: 6.860

4.  Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery.

Authors:  Yoshihiro Nishida; Tadashi Kamada; Reiko Imai; Satoshi Tsukushi; Yoshihisa Yamada; Hideshi Sugiura; Yoji Shido; Junji Wasa; Naoki Ishiguro
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-17       Impact factor: 7.038

Review 5.  Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review.

Authors:  Simon G Launay; Bruno Chetaille; Fanny Medina; Delphine Perrot; Serge Nazarian; Jérôme Guiramand; Laurence Moureau-Zabotto; François Bertucci
Journal:  BMC Cancer       Date:  2011-10-04       Impact factor: 4.430

6.  Safety margins in resection of sacral chordoma: analysis of 18 patients.

Authors:  Adel Refaat Ahmed
Journal:  Arch Orthop Trauma Surg       Date:  2008-06-21       Impact factor: 3.067

7.  Decision making in primary sacral tumors.

Authors:  Ajay Puri; Manish G Agarwal; Mandip Shah; C H Srinivas; P J Shukla; S V Shrikhande; Nirmala A Jambhekar
Journal:  Spine J       Date:  2008-12-06       Impact factor: 4.166

8.  Sacral chordoma: can local recurrence after sacrectomy be predicted?

Authors:  S A Hanna; W J S Aston; T W R Briggs; S R Cannon; A Saifuddin
Journal:  Clin Orthop Relat Res       Date:  2008-06-27       Impact factor: 4.176

9.  Results of carbon ion radiotherapy in 152 patients.

Authors:  Daniela Schulz-Ertner; Anna Nikoghosyan; Christoph Thilmann; Thomas Haberer; Oliver Jäkel; Christian Karger; Gerhard Kraft; Michael Wannenmacher; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-02-01       Impact factor: 7.038

Review 10.  Chordoma: the nonsarcoma primary bone tumor.

Authors:  Rashmi Chugh; Hussein Tawbi; David R Lucas; J Sybil Biermann; Scott M Schuetze; Laurence H Baker
Journal:  Oncologist       Date:  2007-11
View more
  8 in total

Review 1.  Sacral chordoma : A review of literature.

Authors:  S Pillai; S Govender
Journal:  J Orthop       Date:  2018-05-02

2.  Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.

Authors:  Edwin Choy; Laura E MacConaill; Gregory M Cote; Long P Le; Jacson K Shen; Gunnlaugur P Nielsen; Anthony J Iafrate; Levi A Garraway; Francis J Hornicek; Zhenfeng Duan
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

3.  A case-control study of computer navigation assisted resection of primary sacral chordoma above sacrum 3 level.

Authors:  Yongkun Yang; Yuan Li; Qing Zhang; Xiaohui Niu
Journal:  J Bone Oncol       Date:  2020-06-20       Impact factor: 4.072

Review 4.  Local and Distant Recurrence in Resected Sacral Chordomas: A Systematic Review and Pooled Cohort Analysis.

Authors:  Daniel Kerekes; C Rory Goodwin; A Karim Ahmed; Jorrit-Jan Verlaan; Chetan Bettegowda; Nancy Abu-Bonsrah; Daniel M Sciubba
Journal:  Global Spine J       Date:  2018-05-30

5.  Y-box binding protein-1 promotes tumorigenesis and progression via the epidermal growth factor receptor/AKT pathway in spinal chordoma.

Authors:  Chen Liang; Yunlong Ma; Lei Yong; Chenlong Yang; Peng Wang; Xiao Liu; Bin Zhu; Hua Zhou; Xiaoguang Liu; Zhongjun Liu
Journal:  Cancer Sci       Date:  2018-12-19       Impact factor: 6.716

6.  Computer Navigation-aided Resection of Sacral Chordomas.

Authors:  Yong-Kun Yang; Chung-Ming Chan; Qing Zhang; Hai-Rong Xu; Xiao-Hui Niu
Journal:  Chin Med J (Engl)       Date:  2016-01-20       Impact factor: 2.628

7.  The clinical outcome of recurrent sacral chordoma with further surgical treatment.

Authors:  Yongkun Yang; Yuan Li; Weifeng Liu; Hairong Xu; Xiaohui Niu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

8.  A Giant Sacrococcygeal Chordoma: A Case Report.

Authors:  Ehsan Keykhosravi; Hamid Rezaee; Amin Tavallaii; Ahmadreza Tavassoli; Mona Maftouh; Behzad Aminzadeh
Journal:  Brain Tumor Res Treat       Date:  2022-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.